

AN OPERATIONAL AGENDA FOR EU
& NATIONAL POLICY-MAKERS

HOW GOOD ARE OUR MEDICINES?

EUROPEAN HEALTH FORUM GASTEIN

3 OCTOBER 2018

14:45-17:15

Organized by:


Open Society Foundations (OSF),

The European Alliance for Responsible R&D and Affordable
Medicines (European Alliance),

and The European Public Health Alliance (EPHA)



European Alliance for
Responsible R&D and Affordable Medicines



Evidentiary requirements and the medicines regulatory framework in Europe are integral parts of the access to medicines debate and deserve much more attention. This year's session builds on last year's agenda-setting session, and will outline actionable recommendations for medicines regulatory reform in order to achieve meaningful public health needs-driven innovation for the benefit of all patients.



Furthermore, the conference comes at a critical juncture when Europe is debating the role of Health Technology Assessment (HTA), and how to ensure that public investment in medical R&D translates to the medicines we need being developed and made available at prices that patients and governments can afford. The session will draw the link between HTA and the regulatory environment and provide answers to the conundrum of weak evidence-high prices faced by policy-makers across Europe.



#GOODMEDICINES

WELCOMING REMARKS

- Kiti Kajana Phillips, Open Society Foundations

PANEL 1 – Assessing the Quality of Innovation

Open discussion moderated by Yannis Natsis, Policy Manager for Universal Access and Affordable Medicines, EPHA, Board Member, EHFG

- Wolf-Dieter Ludwig, Chairman, Drug Commission, German Medical Association and EMA Management Board member
- Ameet Sarpatwari, PhD.J.D, Instructor in Medicine, Harvard Medical School, Associate Epidemiologist at Brigham and Women's Hospital, Assistant Director of the Program On Regulation, Therapeutics And Law (PORTAL), Harvard University
- Natasha Azzopardi-Muscat, President, European Public Health Association (EUPHA)
- Bart Vermeulen, Deputy Director Healthcare, Office of the Minister of Social Affairs and Public Health, Belgium

PANEL 2 – Case Studies & Tools for Change

Open discussion moderated by Daniel Wolfe, Open Society Foundations

- Caroline Izambert, Citizen advocacy and campaigns coordinator, AIDES, France
- Representative of Altroconsumo
- Adrian van den Hoven, Director General, Medicines for Europe
- Vanessa Lopez, Executive Director of Salud por Derecho (Spain)





European Alliance for
Responsible R&D and Affordable Medicines

Yannis Natsis

European Public Health Alliance (EPHA)
*Policy Manager for Universal Access and
Affordable Medicines*

yannis@epha.org



Co-Funder for
the Health Programme
of the European Union

European Public Health Alliance (EPHA) AISBL
Rue de Treves 49-51, 1040 Brussels (B) • +32 02 230 30 56 • www.epha.org • epha@epha.org
@EPHA_EU • Transparency Register Number: 18941013532-08